Showing all news

Dr. John Stageman Appointed Chair of the Board for MRC Technology

London, UK, 29 September 2014: MRC Technology (MRCT), a UK medical research charity, today announced the appointment of Dr. John Stageman as Chair of its Board of Directors, and who takes over from John Jeans, the charity’s Chair for the last six years. Dr Stageman has a wealth of experience in the pharmaceutical industry and biotechnology research. He has held a number of international R&D senior management roles at AstraZeneca, from drug discovery through to global clinical development. Latterly he led the team responsible for developing AstraZeneca’s competitive… Read More

29 September 2014

SciBX article about the Dementia Consortium

The 24 July issue of SciBX contains an article about the Dementia Consortium with a quote from our Director of Drug Discovery, Justin Bryans. The full article is available on the SciBX site.

24 July 2014

New paper published in EMBO Molecular Medicine

The inwardly rectifying K+ channel KIR7.1 controls uterine excitability throughout pregnancy McCloskey, C., Rada, C., Bailey, E., McCavera, S., van den Berg, H. A., Atia, J., Rand, D. A., Shmygol, A., Chan, Y.-W., Quenby, S., Brosens, J. J., Vatish, M., Zhang, J., Denton, J. S., Taggart, M. J., Kettleborough, C., Tickle, D., Jerman, J., Wright, P., Dale, T., Kanumilli, S., Trezise, D. J., Thornton, S., Brown, P., Catalano, R., Lin, N., England, S. K. and Blanks, A. M. (2014) EMBO Mol Med. doi: 10.15252/emmm.201403944  

24 July 2014

Pembrolizumab in the news

An antibody humanized by MRC Technology has been in the news today, reporting some great results. Merck’s pembrolizumab (or MK3475) is a cancer treatment, in the first instance for melanoma, but is also under investigation for other cancers. It is hoped that it will gain market approval this autumn.

3 June 2014
Showing all news